Posters

Cataract surgery with bilateral vs separate implantation (1 month apart) of diffractive trifocal IOLs: analysis of visual quality and patient preference

Poster Details

First Author: K.Mehta INDIA

Co Author(s):    C. Mehta                    

Abstract Details

Purpose:

To evaluate visual and optical performances of cataract eyes after Phacoemulsification and Trifocal Intraocular Lens (IOL) (AT LISA tri 839MP, Carl Zeiss Meditec) implantation immediate and a month apart.

Setting:

Mehta International Eye Institute

Methods:

Preloaded IOL trifocal IOL (AT LISA tri 839 MP, Carl Zeiss Meditec) was implanted using a BLUEMIXS 180 injector. 100 patients diagnosed with cataracts in both eyes and implanted simultaneously bilaterally with the AT Tri Lisa. In comparison 150 patients had their eyes done at interval from 3 to 6 weeks separately. All the eyes were evaluated 3 months after surgery refractive values and visual acuity (LogMAR), BCVA and UCVA were done. The intermediate visual acuity (AVI 65 cm) were also measured and near (40 cm AVC). Binocular contrast sensitivity was studied with CSV1000 test and Pelli Robson test.

Results:

Examination revealed that the IOLs implanted bilaterally had a faster smoother recovery of vision with far better acceptance and development of multifocality with lesser complaints then the separately implanted grip. Interestingly the ability to drive a car and work on the computer was better. Postoperatively, the following visual and refractive parameters were measured: distance (5m), near (30cm), and intermediate (70 cm) visual acuity, corneal topography and aberrometry, contrast sensitivity and defocus curve. Regular follow-up examinations were performed up to 2 years after surgery.

Conclusions:

AT LISA tri 839 MP provided good distance and near as well as intermediate visual acuity. This lens also improved quality of vision through remarkable diffraction efficiency while maintaining contrast sensitivity. However simultaneous implantation seemed to give measurable better results as compared to separately done implants.

Financial Disclosure:

travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented